Profile data is unavailable for this security.
About the company
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
- Revenue in USD (TTM)3.01bn
- Net income in USD-100.60m
- Incorporated2023
- Employees16.00k
- LocationFortrea Holdings Inc8 Moore DriveDURHAM 27709United StatesUSA
- Fax+1 (302) 636-5454
- Websitehttps://www.fortrea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 1.82bn | 268.00 | -- | 4.11 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 1.85bn | 186.00 | -- | 2.60 | -- | 23.30 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 1.91bn | 55.00 | -- | 5.37 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 1.93bn | 436.00 | -- | 2.11 | -- | 5.35 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.00bn | 64.00 | -- | 3.04 | -- | 273.95 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.01bn | 500.00 | -- | 4.35 | -- | 43.38 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Protagonist Therapeutics Inc | 314.95m | 162.11m | 2.02bn | 124.00 | 14.03 | 3.61 | 12.41 | 6.42 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.05bn | 61.00 | -- | 3.61 | -- | 3,811.72 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.07bn | 557.00 | -- | 3.04 | -- | 1,086.12 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Fortrea Holdings Inc | 3.01bn | -100.60m | 2.10bn | 16.00k | -- | 1.32 | -- | 0.6978 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 2.14bn | 111.00 | -- | 4.06 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.19bn | 91.00 | -- | 2.64 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.21bn | 526.00 | -- | 2.13 | -- | 42.09 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.37bn | 160.00 | -- | 2.82 | -- | 389.80 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.38bn | 988.00 | -- | -- | -- | 2.56 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Data as of Jul 05 2024. Currency figures normalised to Fortrea Holdings Inc's reporting currency: US Dollar USD
59.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 11.02m | 12.33% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.79m | 10.95% |
| Starboard Value LPas of 28 May 2024 | 7.60m | 8.50% |
| Sessa Capital IM LPas of 31 Mar 2024 | 6.38m | 7.13% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2024 | 3.94m | 4.41% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 3.57m | 3.99% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.14m | 3.51% |
| AllianceBernstein LPas of 31 Mar 2024 | 3.08m | 3.45% |
| Gates Capital Management, Inc.as of 31 Mar 2024 | 2.37m | 2.65% |
| Beck, Mack & Oliver LLCas of 31 Mar 2024 | 2.37m | 2.65% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
